Matthew Meyerson is Director of the Center for Cancer Genomics and a member of the Department of Medical Oncology at Dana-Farber Cancer Institute (DFCI); Professor of Genetics and Medicine at Harvard Medical School and an American Cancer Society Research Professor; and an Institute Member in the Cancer Program at the Broad Institute of MIT and Harvard. His laboratory is focused on cancer genomics, the cancer microbiome, and genome-inspired cancer drug discovery. The Meyerson laboratory has discovered many of the major causative somatic mutations in human lung cancer, including epidermal growth factor receptor (EGFR mutations). Dr. Meyerson received an A.B. cum laude in chemistry and physics from Harvard College, an M.D. from Harvard Medical School, and a Ph.D. in biophysics from Harvard University. He was a resident in pathology at Massachusetts General Hospital and a post-doctoral fellow with Robert Weinberg at the Whitehead Institute. Dr. Meyerson joined the faculty of DFCI and Harvard Medical School in 1998 and has mentored a generation of leading researchers in cancer genomics. He has received numerous honors including the Paul Marks Prize in Cancer Research, the Caine Holter Hope Now award from Uniting Against Lung Cancer, the AACR Team Science Award, the Ilchun Memorial Prize, and the Alfred G. Knudson Award in Cancer Genetics. He is an elected member of the National Academy of Medicine, the American Society for Clinical Investigation, and the Association of American Physicians, and an elected fellow of the American Association for the Advancement of Science. Dr. Meyerson is an author of over 300 original scientific publications and an inventor on 19 patents for cancer diagnostics and therapeutics. He was a founder of Foundation Medicine.
Dana-Farber Cancer Institute